Close Menu

Europe

More than a hundred scientific papers are to be retracted because of image reuse concerns, according to the Wall Street Journal.

In Nature this week: method for studying higher-order interactions among genes from single-cell data, and more.

Under the original March agreement, Thermo Fisher was going to pay €39 per Qiagen share, a 23 percent premium that the amendment now raises to 35 percent.

Synlab will make a gastrointestinal testing service that is based on Microba's gut microbiome test available to its network of doctors and clinics.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.

Precommercial firm Enancio has developed lossless compression technology that Illumina hopes will cut sequencing storage costs by 80 percent for its customers.

Analyzing genetic and metabolic data for nearly 16,100 individuals with phenylketonuria, investigators identified disease severity and genotyping gradients, along with predictive clues.

The panel tests for 23 pathogens covering 19 viruses, including SARS-CoV-2, and four bacteria that are responsible for the most frequent respiratory infections.

KogeneBiotech and Trax Management's tests may be performed by any CLIA-certified high-complexity lab, while the Compass test may only be performed by its developer.

By screening more than 1,500 drugs against patient-derived glioblastoma cells, researchers tracked down tumor alterations with apparent ties to proteasome inhibitor response.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.